Northwest Georgia Oncology Centers, P.C.

Summary

Northwest Georgia Oncology Centers, P.C. is a medical facility located in Marietta, Georgia. This center is recognized for care of Breast Cancer, Lung Cancer, Parkinson's disease, Renal Cell Carcinoma, Small Cell Lung Cancer and other specialties. Northwest Georgia Oncology Centers, P.C. is involved with conducting 122 clinical trials across 71 conditions. There are 2 research doctors associated with this hospital, such as Steven L McCune and Steve McCune.

Top PIs

Clinical Trials running at Northwest Georgia Oncology Centers, P.C.

Lung Cancer

Breast Cancer

Chronic Lymphocytic Leukemia

Follicular Lymphoma

Small Cell Lung Cancer

Lymphoma

Pancreatic Cancer

Mantle Cell Lymphoma

Non-Small Cell Lung Cancer

B-Cell Leukemia

Pembrolizumab + Sacituzumab Tirumotecan

for Lung Cancer

This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).

Recruiting

2 awards

Phase 3

2 criteria

MK-2870

for Non-Small Cell Lung Cancer

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypotheses are that sacituzumab tirumotecan is: (1) superior to chemotherapy with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by BICR in NSCLC with EGFR mutations; and (2) superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR mutations.

Recruiting

2 awards

Phase 3

9 criteria

Sacituzumab Tirumotecan vs Standard Therapy

for Lung Cancer

The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to progression-free survival (PFS) and overall survival (OS).

Recruiting

2 awards

Phase 3

2 criteria